Breaking: How Analysts Feel About Catabasis Pharmaceuticals Inc After Today’s Big Decline?

Breaking: How Analysts Feel About Catabasis Pharmaceuticals Inc After Today's Big Decline?

The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is a huge mover today! About 131,530 shares traded hands or 63.54% up from the average. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined 16.15% since April 27, 2016 and is downtrending. It has underperformed by 21.38% the S&P500.
The move comes after 7 months negative chart setup for the $63.16M company. It was reported on Nov, 30 by We have $3.20 PT which if reached, will make NASDAQ:CATB worth $4.42 million less.

Analysts await Catabasis Pharmaceuticals Inc (NASDAQ:CATB) to report earnings on March, 1. They expect $-0.53 EPS, up 15.87% or $0.10 from last year’s $-0.63 per share. After $-0.54 actual EPS reported by Catabasis Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -1.85% EPS growth.

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Ratings Coverage

Out of 2 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Catabasis Pharmaceuticals has been the topic of 4 analyst reports since August 17, 2015 according to StockzIntelligence Inc. Citigroup maintained Catabasis Pharmaceuticals Inc (NASDAQ:CATB) on Thursday, June 9 with “Buy” rating. Wedbush maintained Catabasis Pharmaceuticals Inc (NASDAQ:CATB) on Wednesday, June 8 with “Outperform” rating. Wedbush maintained the shares of CATB in a report on Monday, August 17 with “Buy” rating. The firm earned “Buy” rating on Tuesday, March 22 by Citigroup.

According to Zacks Investment Research, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”

More notable recent Catabasis Pharmaceuticals Inc (NASDAQ:CATB) news were published by: which released: “Catabasis shares plummet 51% after drug trial misses goal” on April 24, 2015, also with their article: “News Catabasis Pharmaceuticals Inc.CATB” published on February 02, 2015, published: “Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) to Ring The Nasdaq Stock Market …” on November 16, 2016. More interesting news about Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were released by: and their article: “Catabasis Pharmaceuticals Initiates MoveDMD, a Phase 1/2 Trial of CAT-1004 for …” published on June 17, 2015 as well as‘s news article titled: “Catabasis Pharmaceuticals Shares Could Double” with publication date: July 20, 2015.

CATB Company Profile

Catabasis Pharmaceuticals, Inc., incorporated on June 26, 2008, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Firm is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. The Company’s CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment